P2Y2R-mediated transactivation of VEGFR2 through Src phosphorylation is associated with ESM-1 overexpression in radiotherapy-resistant-triple negative breast cancer cells

被引:1
|
作者
Jin, Hana [1 ]
Ko, Young Shin [1 ,2 ]
Yun, Seung Pil [1 ,2 ]
Park, Sang Won [1 ,2 ]
Kim, Hye Jung [1 ,2 ,3 ]
机构
[1] Gyeongsang Natl Univ, Inst Hlth Sci, Coll Med, Dept Pharmacol, Jinju 52727, Gyeongsangnamdo, South Korea
[2] Gyeongsang Natl Univ, Dept Convergence Med Sci, Jinju 52727, Gyeongsangnamdo, South Korea
[3] Gyeongsang Natl Univ, Inst Hlth Sci, Coll Med, Dept Pharmacol, 816 Beongil 15 Jinjudaero, Jinju 52727, Gyeongsangnamdo, South Korea
基金
新加坡国家研究基金会;
关键词
endothelial-specific molecule-1; P2Y(2) purinergic receptor; vascular epithelial growth factor receptor 2; transactivation; radiotherapy-resistant triple negative breast cancer cells; ENDOTHELIAL GROWTH-FACTOR; RECEPTOR; ENDOCAN; EXPRESSION; MOLECULE-1; BINDING; ACTIVATION; IMPACT;
D O I
10.3892/ijo.2023.5521
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We previously reported that radiotherapy-resistant (RT-R) triple negative breast cancer (TNBC) cells upregulate the expression of endothelial-specific molecule-1 (ESM-1) compared with TNBC cells. In addition, ESM-1 is involved in an increased proliferation and invasion of RT-R-TNBC cells compared with TNBC cells. It was further identified that, in RT-R-TNBC cells, P2Y(2) purinergic receptor (P2Y(2)R)-mediated activation of p21-activated kinase 1 (PAK1), protein kinase C (PKC), c-Jun N-terminal kinase (JNK) and p38 MAPKs is related to ESM-1 expression via forkhead box O1 (FoxO1) regulation. Notably, it has been reported that P2Y(2)R mediates the transactivation of vascular epithelial growth factor receptor 2 (VEGFR2), and VEGFR2 is known to be involved in ESM-1 expression. Therefore, in the present study, the involvement of VEGFR2 in the P2Y(2)R-mediated ESM-1 upregulation in RT-R-TNBC cells and the relationship between P2Y(2)R and VEGFR2 activation was further examined. Western blotting and reverse transcription-PCR were used to monitor the expression of ESM-1, and the results demonstrated that extracellular ATP treatment regulated the expression of ESM-1 in a P2Y(2)R-dependent manner in RT-R-MDA-MB-231 cells. In addition, extracellular ATP activated Src and VEGFR2 after 5 min of incubation, which was abolished by knockdown of P2Y(2)R expression. VEGFR2 activation in response to ATP was also decreased by inhibiting Src activity, suggesting that ATP-activated P2Y(2)R regulates VEGFR2 phosphorylation via Src activation. Furthermore, ATP-induced ESM-1 expression was decreased by transfection with VEGFR2 small interfering RNA (siRNA). ESM-1-related signaling molecules, PAK1, PKC, JNK and p38 MAPKs, and the transcriptional regulator, FoxO1, which were activated by ATP, were also decreased following transfection with VEGFR2 siRNA. These results suggest that P2Y(2)R-mediated transactivation of VEGFR2 through Src phosphorylation is associated with ESM-1 overexpression in RT-R-TNBC cells.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] P2Y2R-mediated inflammasome activation is involved in tumor progression in breast cancer cells and in radiotherapy-resistant breast cancer
    Jin, Hana
    Ko, Young Shin
    Kim, Hye Jung
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2018, 53 (05) : 1953 - 1966
  • [2] P2Y2R-Mediated PAK1 Activation Is Involved in ESM-1 Overexpression in RT-R-MDA-MB-231 through FoxO1 Regulation
    Jin, Hana
    Kim, Hye Jung
    CANCERS, 2022, 14 (17)
  • [3] Preclinical Evaluation of a Novel Orally Available SRC/Raf/VEGFR2 Inhibitor, SKLB646, in the Treatment of Triple-Negative Breast Cancer
    Zheng, Ming-Wu
    Zhang, Chun-Hui
    Chen, Kai
    Huang, Mei
    Li, Ya-Ping
    Lin, Wan-Ting
    Zhang, Rong-Jie
    Zhong, Lei
    Xiang, Rong
    Li, Lin-Li
    Liu, Xin-Yu
    Wei, Yu-Quan
    Yang, Sheng-Yong
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (03) : 366 - 378
  • [4] Evaluation of EGFR, VEGFR2, IGF-1R and HIF-1a Expression and Their Prognostic Value in Iranian Triple-negative Breast Cancer Patients
    Mehdizadeh, R.
    Najafi, S.
    Jahanzad, I.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S145 - S145
  • [5] M2 macrophage-induced lncRNA PCAT6 facilitates tumorigenesis and angiogenesis of triple-negative breast cancer through modulation of VEGFR2
    Fang Dong
    Shengnan Ruan
    Jinlong Wang
    Yun Xia
    Kehao Le
    Xiaoyun Xiao
    Ting Hu
    Qiong Wang
    Cell Death & Disease, 11
  • [6] M2 macrophage-induced lncRNA PCAT6 facilitates tumorigenesis and angiogenesis of triple-negative breast cancer through modulation of VEGFR2
    Dong, Fang
    Ruan, Shengnan
    Wang, Jinlong
    Xia, Yun
    Le, Kehao
    Xiao, Xiaoyun
    Hu, Ting
    Wang, Qiong
    CELL DEATH & DISEASE, 2020, 11 (09)
  • [7] Correction: M2 macrophage-induced lncRNA PCAT6 facilitates tumorigenesis and angiogenesis of triple-negative breast cancer through modulation of VEGFR2
    Dong, Fang
    Ruan, Shengnan
    Wang, Jinlong
    Xia, Yun
    Le, Kehao
    Xiao, Xiaoyun
    Hu, Ting
    Wang, Qiong
    CELL DEATH & DISEASE, 2022, 13 (08)
  • [8] Correction: M2 macrophage-induced lncRNA PCAT6 facilitates tumorigenesis and angiogenesis of triple-negative breast cancer through modulation of VEGFR2
    Fang Dong
    Shengnan Ruan
    Jinlong Wang
    Yun Xia
    Kehao Le
    Xiaoyun Xiao
    Ting Hu
    Qiong Wang
    Cell Death & Disease, 13
  • [9] SKP2 Overexpression Is Associated With Increased Serine 10 Phosphorylation of p27 (pSer10p27) in Triple-Negative Breast Cancer
    Fagan-Solis, Katerina D.
    Pentecost, Brian T.
    Gozgit, Joseph M.
    Bentley, Brooke A.
    Marconi, Sharon M.
    Otis, Christopher N.
    Anderton, Douglas L.
    Schneider, Sallie Smith
    Arcaro, Kathleen F.
    JOURNAL OF CELLULAR PHYSIOLOGY, 2014, 229 (09) : 1160 - 1169
  • [10] ProNGF promotes brain metastasis through TrkA/EphA2 induced Src activation in triple negative breast cancer cells
    Julien Cicero
    Sarah Trouvilliez
    Martine Palma
    Gaetan Ternier
    Laurine Decoster
    Eloise Happernegg
    Nicolas Barois
    Alexandre Van Outryve
    Lucie Dehouck
    Roland P. Bourette
    Eric Adriaenssens
    Chann Lagadec
    Cagatay Mehmet Tarhan
    Dominique Collard
    Zied Souguir
    Elodie Vandenhaute
    Grégory Maubon
    François Sipieter
    Nicolas Borghi
    Fumitaka Shimizu
    Takashi Kanda
    Paolo Giacobini
    Fabien Gosselet
    Nathalie Maubon
    Xuefen Le Bourhis
    Isabelle Van Seuningen
    Caroline Mysiorek
    Robert-Alain Toillon
    Experimental Hematology & Oncology, 12